[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphoma-extranodal-nk-t-cell\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphoma-extranodal-nk-t-cell":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100560130","phase-2-selinexor-anti-pd-1-antibody-plus-golidocitinib-in-rr-nktcl-100560130",false,"NCT06573138","Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R\u002FR NKTCL","The Efficacy and Safety of Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in the Treatment of Relapsed or Refractory Natural Killer \u002F T-cell Lymphoma","Inclusion Criteria:\n\n1. Confirmed histological diagnosis of NKTCL nasal type\n2. The subject had received prior adequate anti-lymphoma therapy containing asparaginase\n3. Age 14-75 years old\n4. expected to live longer than 3 months\n5. At least one measurable\u002Fevaluable site after diagnostic biopsy before treatment start\n6. ECOG performance status of 0-2\n7. Adequate hematological and organ function; i.e. ANC \\>1000 cells \u002Fmmc, platelet counts \\> 50.000\u002Fmmc, Hemoglobin \\> 9 g\u002Fdl AST, ALT \\\u003C3 x ULN; serum bilirubin \\\u003C 1.5x ULN (patient with Gilbert disease can be enrolled)Serum creatinine \\\u003C 2 x ULN or creatinine clearance \\> 50ml\u002Fmin\n8. Tumor tissue (fresh preferred, archival tissue is also acceptable)\n9. For women of childbearing potential a negative pregnancy test on day 1 of cycle 1 and agree to adopt adequate measure to avoid pregnancy during study treatment and for at least one year from EOT.\n10. For men agreement to remain abstinent or to use barrier contraception\n11. Signed Informed consent\n\nExclusion Criteria:\n\n1. Confirmed histological diagnosis of aggressive NK cell leukemia\n2. Evidence of suspect of CNS disease.\n3. Has an active autoimmune disease that has required systemic treatment in past 2-years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs), including but not limited to myotonia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associate with antiphospholipid syndrome, wegener's granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis or glomerulonephritis. The following exception are allowed: patients with autoimmune related hypothyroidism or type I diabetes mellitus who are on stable treatment. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n4. Treatment with systemic immunosuppressive medications, including prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide and anti-tumor necrosis factor (anti-TNF) agents within 2 weeks prior to cycle 1 day 1; inhaled corticosteroids are allowed.\n5. Active infection requiring systemic therapy\n6. History of (non-infectious) pneumonitis that required steroids; evidence of interstitial lung disease or active, non-infectious pneumonitis\n7. Significant cardiovascular disease, myocardial infarction in the previous 3 months, unstable arrhythmias, or unstable angina.\n8. History of other(s) infiltrating cancer(s) in the previous 3 years that were not treated with curative intent or who are still receiving anticancer therapy (including hormone therapy for breast or prostate cancer).\n9. HBsAg, HCV or HIV positivity. Positive serology is admitted for HBV and HCV but DNA\u002FRNA test must be negative\n10. Pregnant or lactating women\n11. Administration of a live attenuated vaccine within 4 weeks before cyle 1 day 1. Patients must not receive live, attenuate vaccines, including influenza vaccines at any time during study.\n12. Other uncontrollable medical condition that may interfere the participation of the study","ALL","14 Years","75 Years",{"count":20,"type":21},18,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer \u002F T-cell lymphoma.",[27],"Lymphoma, Extranodal NK-T-Cell","NOT_YET_RECRUITING","2024-08-23",{"date":31,"type":32},"2024-08-27","ACTUAL",{"date":34,"type":21},"2024-09-01",{"date":36,"type":21},"2027-07-01",{"name":38,"class":39},"Ruijin Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":5},"100274987","phase-2-allogeneic-stem-cell-transplantation-in-relapsedrefractory-t--nkt-cell-lymphomas-100274987","NCT02859402","Allogeneic Stem Cell Transplantation in Relapsed\u002FRefractory T-, NK\u002FT-cell Lymphomas","Allogeneic Stem Cell Transplantation With 3-days Busulfan Plus Fludarabine as Conditioning in Patients With Relapsed or Refractory T-, NK\u002FT-cell Lymphomas","RRTCLAlloSCT","Inclusion Criteria:\n\n1. Age 19 - 65\n2. Histologically confirmed T or NK cell lymphomas :\n\n   * anaplastic large cell lymphoma\n   * angioimmunoblastic T-cell lymphoma,\n   * peripheral T-cell lymphoma, NOS\n   * NK\u002FT-cell lymphoma\n3. Relapsed after or refractory to one or more of previous chemotherapy including frontline autologous HSCT.\n4. At least one measured lesion using conventional CT or PET CT at the time of relapse after or refractory to one or more of previous chemotherapy and before salvage chemotherapy\n5. Complete or Partial response after short cycles of salvage chemotherapy\n6. Patients who have HLA full-match (8\u002F8 in HLA-A, B, C, DR by DNA high-resolution technique) or one-locus mismatch (7\u002F8) sibling, or unrelated bone marrow or peripheral blood or cord blood stem cell donors\n7. ECOG performance status ≤ 2\n8. Charlson Comorbidity Index (CCI) before HSCT ≤ 3\n9. Adequate renal function : serum creatinine level \\\u003C 2.0 mg\u002FdL\n10. Adequate liver function :\n\n    * Transaminase (AST\u002FALT) \\\u003C 3 X upper normal value (or \\\u003C 5 x ULN in the presence of lymphoma involvement of the liver)\n    * Total bilirubin \\\u003C 2 X upper normal value (or \\\u003C 5 x ULN in the presence of NK\u002FT involvement of the liver)\n11. Cardiac ejection fraction ≥ 50 % as measured by MUGA or 2D ECHO without clinically significant abnormality\n12. No clinically significant infection\n13. No clinically significant bleeding symptoms or sign\n14. Patients who decided to participate in this study and signed for a written consent\n\nExclusion Criteria:\n\n1. Adult T cell leukemia\u002Flymphoma, Lymphoblastic lymphoma, Primary cutaneous CD30+ T cell disorders Mycosis fungoides, Sezary SD\n2. Patients who have previously performed Allo-HSCT\n3. T cell lymphoma with primary central nervous system (CNS) Involvement.\n\n   \\*\\* However, patients who have only had prophylactic intrathecal or intravenous chemotherapy against CNS disease are eligible.\n4. Patients with a known history of HIV seropositivity or HCV (+).\n\n   \\*\\* Patients with HBV are eligible. However, primary prophylaxis using antiviral agents is recommended for HBV carrier or prevent HBV reactivation during whole treatment period.\n5. Any other malignancies within the past 5 years\n\n   \\*\\* Except curatively treated non-melanoma skin cancer or in situ carcinoma of cervix uteri\n6. Ejection fraction \\\u003C 50% by a echocardiography\n7. FEV1 \\\u003C60% or DLCO \\\u003C60% by a pulmonary function test\n8. ECOG performance status 3 or 4\n9. Combined serious medical problem or disease\n\n   * Serious or unstable heart disease although proper treatment\n   * Myocardial infarction in recent 3 months\n   * Underlying serious neurologic or psychiatric disease including dementia or seizure\n   * Active uncontrolled infection including hepatitis B and C\n   * Serious other medical problems observed by the doctors in charge of the patient\n10. Pregnant or lactating women, women of childbearing potential not employing adequate contraception",true,"19 Years","65 Years",{"count":52,"type":21},34,[24],"Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients. This clinical trial is studying the efficacy and safety of busulfan plus fludarabine as conditioning therapy followed by allogeneic stem cell transplantation (Allo-SCT) in T- and NK\u002FT-cell lymphoma patients who have relapsed or are refractory to previous chemotherapies including autologous transplantation.",[56,27],"T-cell Non-Hodgkin Lymphoma",[56,58,59,60,61],"NK\u002FT-cell Non-Hodgkin Lymphoma","Relapsed, refractory","Conditioning","Allogeneic stem cell transplantation","RECRUITING","2022-08-17",{"date":65,"type":32},"2022-08-18",{"date":67,"type":32},"2016-12",{"date":69,"type":21},"2027-12",{"name":71,"class":39},"Keimyung University Dongsan Medical Center"]